Cellgram CKD
Alternative Names: Allogeneic bone marrow-derived mesenchymal stem cell therapy; Cellgram-CKD; Cellgram_CKDLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Pharmicell
- Developer Asan Medical Center; Pharmicell
- Class Mesenchymal stem cell therapies
- Mechanism of Action Angiogenesis modulating agents; Apoptosis inhibitors; Cell replacements; Immunogenetic modulators; Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Renal failure
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Renal-failure in South Korea (IV, Injection)
- 01 Nov 2021 Pharmicell plans a long-term follow-up study for Renal failure in South Korea (IV) (NCT05096182)
- 16 Sep 2021 Phase I clinical trials in Renal failure in South Korea (IV) (NCT05042206) (Pharmicell pipeline, September 2021)